René S Kahn, John M Kane, Christoph U Correll, Christina Arevalo, Adam Simmons, Christine Graham, Sergey Yagoda, Beibei Hu, David McDonnell
Objective: Patients with early-phase schizophrenia or bipolar I disorder (BD-I) are at greater risk for antipsychotic-associated weight gain. This 12-week, randomized, double-blind study conducted between June 2017 and December 2021 evaluated weight effects of combination olanzapine and samidorphan (OLZ/SAM) versus olanzapine in early-phase illness. Methods: Young adults (16-39 years) with DSM-5 schizophrenia, schizophreniform disorder, or BD-I, < 4 years since symptom onset, body mass index < 30 kg/m2 , and < 24 weeks' cumulative antipsychotic exposure were randomized to OLZ/SAM (5-20/10 mg/d) or olanzapine (5-20 mg/d)...
March 22, 2023: Journal of Clinical Psychiatry
Anna D Burke, Danielle Goldfarb
Recent advances in technology can lead to earlier detection of Alzheimer disease (AD) in patients and therefore opportunities for early diagnosis and treatment. In addition, novel agents can slow disease progression and improve symptoms. However, clinicians are not providing a diagnosis to over half of individuals who meet criteria for dementia. Early detection and intervention are crucial to slow symptom progression, and these advances provide a window of opportunity to diagnose the disease early and even prevent it from becoming symptomatic...
March 22, 2023: Journal of Clinical Psychiatry
Eric J Lenze, Angela M Reiersen, Charles F Zorumski, Paramala J Santosh
Importance: "Psychotropic" drugs have widespread reach and impact throughout the brain and body. Thus, many of these drugs could be repurposed for non-psychiatric indications of high public health impact. Observations: The selective serotonin reuptake inhibitor (SSRI) fluvoxamine was shown efficacious as a COVID-19 treatment based on randomized controlled trials (RCTs), and a benefit of other antidepressants has been posited based on observational and preclinical studies. In this review, we illuminate features of SSRIs and other psychiatric drugs that make them candidates to repurpose for non-psychiatric indications...
March 20, 2023: Journal of Clinical Psychiatry
Joseph F Goldberg
No abstract text is available yet for this article.
March 20, 2023: Journal of Clinical Psychiatry
Kristina M Deligiannidis, Anita H Clayton
Major depressive disorder (MDD) and major depressive episode with peripartum onset, commonly referred to as postpartum depression (PPD), are among the most common psychiatric illnesses and are leading contributors to disability and suicide. Standard of care antidepressants are the cornerstone of MDD treatment; however, nonadherence to antidepressants has been widely recognized as one of the reasons for treatment failure in MDD. Delayed response in current therapies can take up to 4 or even 8 weeks for patients to experience therapeutic benefits...
March 16, 2023: Journal of Clinical Psychiatry
Brian J Lee, Robert O Cotes, Ramin Mojtabai, Russell L Margolis, Frederick C Nucifora, Paul S Nestadt
Objective: Clozapine is the most efficacious antipsychotic medication, but it is underutilized and its mechanism of action is still poorly understood. One aspect of its unique efficacy that requires further study is its effect on suicidality. A randomized controlled trial, the InterSePT study, yielded evidence that clozapine reduces suicidality more than olanzapine, after which it became the only medication indicated for recurrent suicidal behavior in schizophrenia and schizoaffective disorder. We present here the first study of population mortality data to investigate the effect of clozapine on suicide...
March 15, 2023: Journal of Clinical Psychiatry
Ana Izquierdo, María Cabello, Itziar Leal, Iosune Torio, José L M Madrigal, Karina S MacDowell, Roberto Rodriguez-Jimenez, David Rentero, Ángela Ibáñez, Miriam Ayora, Covadonga M Díaz-Caneja, Renzo Abregú-Crespo, Blanca Mellor-Marsá, Marina Díaz-Marsá, Norberto Malpica, María-Fé Bravo-Ortiz, Enrique Baca-García, Celso Arango, Jose Luis Ayuso-Mateos
Objective: Neighborhood socioeconomic status seems to be related to functioning in patients with first episode of psychosis (FEP). The present study aimed to assess if neighborhood vulnerability and risk of social exclusion could predict functional outcomes in people with FEP after controlling for other key variables identified in previous literature. Methods: A total of 137 patients with FEP ( DSM-IV-TR criteria) and 90 controls comprised the study sample from February 2013 to May 2019. Functioning was assessed with the WHO Disability Assessment Schedule...
March 13, 2023: Journal of Clinical Psychiatry
Mete Ercis, Aysegul Ozerdem, Balwinder Singh
No abstract text is available yet for this article.
March 8, 2023: Journal of Clinical Psychiatry
Sudie E Back, Julianne C Flanagan, Jim Mintz, Kathleen T Brady, Jennifer Jones, Amber M Jarnecke, Jane E Joseph, David W Shirley, Robert J Malcolm, Mark Hamner, Brett T Litz, Barbara L Niles, Stacey Young-McCaughan, Terence M Keane, Alan L Peterson
Objective: The aim of this study was to determine the efficacy of doxazosin, an α1 -adrenergic antagonist, for the treatment of co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Methods: This 12-week, double-blind, randomized controlled trial of doxazosin (16 mg/d) was conducted between June 2016 and December 2019 at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. Participants were military veterans (N = 141) who met DSM-5 criteria for current PTSD and AUD and were randomly assigned to receive doxazosin (n = 70) or placebo (n = 71)...
March 8, 2023: Journal of Clinical Psychiatry
Leslie Citrome, Suresh Durgam, John B Edwards, Robert E Davis
Objective: To describe lumateperone for the treatment of schizophrenia in adults using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). Methods: Data were obtained from the 3 phase 2/3 lumateperone trials, conducted between 2011 and 2016, in patients with schizophrenia diagnosed using the Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition, Text Revision, or Fifth Edition. Efficacy was assessed using various response criteria; tolerability was principally assessed using rates of adverse events (AEs)...
March 6, 2023: Journal of Clinical Psychiatry
Clare L Taylor, Hilary K Brown, Natasha R Saunders, Lucy C Barker, Simon Chen, Eyal Cohen, Cindy-Lee Dennis, Joel G Ray, Simone N Vigod
Objective: To compare well-baby visit and vaccination schedule adherence up to age 24 months in children of mothers with versus without schizophrenia. Methods: Using administrative health data on births in Ontario, Canada (2012-2016), children of mothers with schizophrenia ( ICD-9 : 295; ICD-10 : F20/F25; DSM-IV schizophrenia or schizoaffective disorder) (n = 1,275) were compared to children without maternal schizophrenia (n = 520,831) on (1) well-baby visit attendance, including an enhanced well-baby visit at age 18 months, and (2) vaccine schedule adherence for diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B (DTaP-IPV-Hib), and measles, mumps, rubella (MMR)...
March 1, 2023: Journal of Clinical Psychiatry
Tanner J Bommersbach, Robert A Rosenheck, Taeho Greg Rhee
Background: Suicide prevention is a major public health priority. The effectiveness of suicide prevention initiatives is typically assessed by reductions in incidents of suicidal behavior. However, the association of suicide attempts with changes in measures of overall health-related quality of life (HRQOL) has been understudied. Methods: Nationally representative data from 36,309 adults from the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions Wave III (NESARC-III) were used to compare 3 groups: individuals with any suicide attempt in the past 3 years, individuals with a suicide attempt prior to the past 3 years, and those with no prior attempts...
February 27, 2023: Journal of Clinical Psychiatry
Min Kai Chan, Qian Hui Chew, Kang Sim
Objective: A systematic review was conducted to examine resilience in bipolar disorder (BD) and its relationship to demographic, psychopathology, illness features, and psychosocial functioning. Data Sources: A literature search was conducted from database inception to August 2022 using PubMed, Web of Science, EMBASE, and PsycINFO. Reference lists were also manually searched for relevant articles. Study Selection: Studies were included if they involved patients with a primary diagnosis of BD, were published in English, and measured resilience using a clearly defined rating scale...
February 22, 2023: Journal of Clinical Psychiatry
Timothy E Wilens, Janet R Wozniak, Lee S Cohen, Maurizio Fava, Jerrold F Rosenbaum
No abstract text is available yet for this article.
February 22, 2023: Journal of Clinical Psychiatry
Anita H Clayton, Robert Lasser, Indrani Nandy, Abdul J Sankoh, Jeffrey Jonas, Stephen J Kanes
Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive steroid and GABAA receptor positive allosteric modulator, in major depressive disorder (MDD). Methods: The phase 3, double-blind, randomized, placebo-controlled MOUNTAIN study enrolled adult outpatients with DSM-5 -diagnosed MDD, 17-item Hamilton Depression Rating Scale total score (HDRS-17) ≥ 22, and Montgomery-Asberg Depression Rating Scale total score ≥ 32. Patients were randomized to treatment with zuranolone 20 mg, zuranolone 30 mg, or placebo for 14 days, followed by an observation period (days 15-42) and an extended follow-up (days 43-182)...
February 20, 2023: Journal of Clinical Psychiatry
Oguz K Karamustafalıoğlu, Leah Fostick, Mehmet Çevik, Gil Zukerman, Onur Tankaya, Mustafa Güveli, Banadir Bakım, Nesrin Karamustafalıoğlu, Joseph Zohar
Objective: Few earthquake survivor studies extend follow-up beyond 2 years, leaving the long-term course of earthquake-related posttraumatic stress disorder (PTSD) unknown. This 10-year survey re-assessed the 1999 İzmit, Turkey, earthquake survivors. Methods: İzmit earthquake survivors (N = 198), previously assessed for PTSD/partial PTSD at 1-3 months and 18-20 months post-earthquake, were evaluated 10 years post-event from January 2009 through December 2010. A PTSD self-test (Turkish translation) used DSM-IV criteria to characterize full PTSD, "stringent partial PTSD," "lenient partial PTSD," or non-PTSD based on symptom type/amount...
February 20, 2023: Journal of Clinical Psychiatry
Hanga Galfalvy, Anna Szücs, Ya-Wen Chang, Morgan Buerke, Katalin Szanto
Objective: In young and middle-aged adults, suicidal ideation is an important predictor of prospective suicide attempts, but its predictive power in late life remains unclear. In this study, we used Latent Profile Analysis (LPA) in a cohort of depressed older adults to identify distinct ideation profiles and their clinical correlates and test their association with risk of suicidal behavior longitudinally. Methods: A total of 337 depressed older adults (aged 50-93 years) were assessed for suicidal ideation and behavior for up to 14 years (median = 3 years), at least once per year (study period: 2002-2020)...
February 15, 2023: Journal of Clinical Psychiatry
Jose M Rubio, Marko A Mychaskiw, Sangtaeck Lim, Mark Suett, Yitong Wang, Marc Tian, John M Kane
Objective: Long-acting injectable antipsychotic agents (LAIs) have improved clinical effectiveness and adherence versus oral antipsychotic agents (OAs); however, a minority of individuals with schizophrenia are treated with LAIs compared with OAs. This cohort study aimed to evaluate predictors of initiation of atypical LAIs among patients with newly diagnosed schizophrenia in the United States. Methods: Using claims data from IBM MarketScan Commercial and Medicare Supplemental databases between January 1, 2013, and March 31, 2020, adults with first diagnosis of schizophrenia, ≥ 1 OA claim following diagnosis, and continuous benefits were identified...
February 13, 2023: Journal of Clinical Psychiatry
Michel Sabé, Konstantinos Pallis, Marco Solmi, Alessio Crippa, Othman Sentissi, Stefan Kaiser
Objective: To investigate the association of metabolic side effects with antipsychotic dose, we conducted a dose-response meta-analysis of randomized controlled trials (RCTs) in which antipsychotics were administered to people with schizophrenia. The primary outcome was mean change in weight. The secondary outcomes were the mean changes in metabolic parameters. Data Sources: MEDLINE, Embase, PubMed, PsyARTICLES, PsycINFO, Cochrane Database of Systematic Reviews, and different trial registries were searched for articles published in English until February 2021...
February 8, 2023: Journal of Clinical Psychiatry
Aaron E Philipp-Muller, Callum J Stephenson, Elnaz Moghimi, Amir H Shirazi, Roumen Milev, Gustavo Vazquez, Taras Reshetukha, Nazanin Alavi
No abstract text is available yet for this article.
February 6, 2023: Journal of Clinical Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.